Patents
Literature
37 results about "Dopaminergic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dopaminergic means "related to dopamine" (literally, "working on dopamine"), dopamine being a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain. Dopaminergic brain structures facilitate dopamine-related activity. For example, certain proteins such as the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT₂), and dopamine receptors can be classified as dopaminergic, and neurons that synthesize or contain dopamine and synapses with dopamine receptors in them may also be labeled as dopaminergic. Enzymes that regulate the biosynthesis or metabolism of dopamine such as aromatic L-amino acid decarboxylase or DOPA decarboxylase, monoamine oxidase (MAO), and catechol O-methyl transferase (COMT) may be referred to as dopaminergic as well. Also, any endogenous or exogenous chemical substance that acts to affect dopamine receptors or dopamine release through indirect actions (for example, on neurons that synapse onto neurons that release dopamine or express dopamine receptors) can also be said to have dopaminergic effects, two prominent examples being opioids, which enhance dopamine release indirectly in the reward pathways, and some substituted amphetamines, which enhance dopamine release directly by binding to and inhibiting VMAT₂.
Composition and Method for Treating Metabolic Disorders
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
Owner:VEROSCIENCE LLC
C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof
The present invention provides a C-terminal CDNF fragment sequence or a sequence which has at least 80% homology or sequence identity to said sequence. The C-terminal CDNF fragment protects ER stressed neurons, motoneurons and dopaminergic neurons and the fragment is capable of penetrating neuronal cell membrane as well as the blood-brain-barrier. The present invention further provides said fragment and pharmaceutical compositions comprising said fragment for use in treatments of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders. The present invention is also providing a C-terminal MANF fragment sequence or a sequence which has at least 80% homology or sequence identity to the said sequence and pharmaceutical compositions comprising said MANF fragment for use in the treatment of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders.
Owner:MYNEUROCURE OY
Dopamine D2 receptor ligands
The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.
Owner:THE BROAD INST INC +1
Digital therapeutics and combination therapy for the treatment of parkinsons disease
Provided is a method of digital therapeutics for modulating one or more Parkinson's disease-related markers, symptoms, or disease progression in an individual, on a standalone basis or by combining them with medicinal agents, particularly dopaminergic agents. Also provided are corresponding systems for implementing, delivering, and adapting such therapeutic interventions.
Owner:REMEPY HEALTH LTD
Composition and method for treating metabolic disorders
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
Owner:VEROSCIENCE LLC
Low-dose dopaminergic drugs to delay the progression of spinocerebellar ataxia type 3 and alzheimer's disease
PCT designated stageWO2025230432A1Nervous disorderKetone active ingredientsDepressantPharmaceutical formulation
The present invention refers to dopaminergic drugs such as dopamine precursors and aromatic L-amino acid decarboxylase (AADC) inhibitors for use in a treatment to delay the progression of pathologies in which abnormal amyloid deposits spread to different brain regions, consisting of Spinocerebellar Ataxia Type 3 and Alzheimer's Disease, administered in levodopa-equivalent doses below 300 mg / day. The present invention further refers to pharmaceutical formulations comprising the said dopaminergic drugs. The present invention's compounds pharmaceutical formulations and uses may be advantageously employed in a treatment to prevent further accumulation of amyloid deposits in neurons, and minimize adverse effects associated with the prolonged use of dopamine precursors and / or their peripheral degradation.
Owner:I3S - INST OF HEALTH RES & INNOVATION ASSOC
Digital therapeutics and combination therapy for the treatment of parkinson's disease
PCT designated stageWO2026099869A1Physical therapies and activitiesOrganic active ingredientsPharmacy medicineDopaminergic
Provided is a method of digital therapeutics for modulating one or more Parkinson's disease-related markers, symptoms, or disease progression in an individual, on a standalone basis or by combining them with medicinal agents, particularly dopaminergic agents. Also provided are corresponding systems for implementing, delivering, and adapting such therapeutic interventions.
Owner:REMEPY HEALTH LTD
Method for identifying dopaminergic neurons and progenitor cells
This provides a molecular diagnostic tool useful for the efficient and accurate characterization of the discriminative and functional properties of iPSC-derived dopaminergic neurons. [Solution] A computer-based method for identifying determined dopaminergic progenitor cells within an in vitro population of neural progenitor cells is provided, comprising: receiving a test dataset containing data such as gene expression profile information relating to an in vitro population of neural progenitor cells; querying a gene expression reference database and comparing the test dataset with the gene expression reference database, wherein the gene expression reference database contains gene expression profile information of the desired determined dopaminergic progenitor cells; and outputting a computer-calculated label classification that includes an indication of whether or not the in vitro population of neural progenitor cells contains the determined dopaminergic progenitor cells.
Owner:THE SCRIPPS RES INST +1
In-vitro preparation method for midbrain dopaminergic progenitor cell population
PCT designated stageWO2025252180A1Nervous disorderMicrobiological testing/measurementProgenitorMidbrain
Provided is a method for differentiating pluripotent stem cells in vitro to prepare a cell population mainly composed of midbrain floor plate dopaminergic progenitor cells, wherein the progenitor cells can efficiently and directionally differentiate into midbrain dopaminergic neuron precursors and midbrain dopaminergic neurons after being transplanted into a subject. Further provided is a cell population prepared by the method, a pharmaceutical composition containing the cell population, and a method for using the cell population or the pharmaceutical composition to treat or ameliorate a neurological disorder caused by a reduction in the number of midbrain dopaminergic neurons and / or impairment of function thereof.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI +1
A highly sensitive screening method for thyroid hormone disruptors
The present application relates to a kind of thyroid hormone interferent high-sensitivity screening method, belong to new pollutant screening method technical field.The present application is based on the biological recognition performance of polypeptide and the peroxidase-like activity of nano gold combined with polypeptide material, based on this, a kind of thyroid hormone interferent screening method under medium alkaline condition can guarantee the activity of polypeptide and also can play the enzyme activity of nano gold.The dopamine can be catalyzed by nano gold under medium alkaline condition and quickly generate red product.Once interferent combines specific recognition polypeptide, occupies the enzyme activity recognition site of nano gold, reduces enzyme activity, in dopamine color system, different absorbance values are shown, so as to show the thyroid hormone interference toxic effect, reach the purpose of recognizing thyroid hormone interferent.The method does not need to use a large amount of organic solvent, and toxicity evaluation of thyroid hormone interferent can be realized by absorbance determination, with the advantages of simple preparation, low cost, high sensitivity.
Owner:HUAZHONG UNIV OF SCI & TECH
In vitro differentiation method of stem cells
Provided are methods for in vitro induced differentiation of embryonic stem cells or pluripotent stem cells into dopaminergic neural progenitor cells, dopaminergic neural precursor cells and / or dopaminergic neurons. Also provided are media for use in the method, cell populations obtained using the method, and the use of the obtained cell populations in the prevention and / or treatment of diseases and / or dysfunctions associated with dopaminergic neuron degenerative disorders.
Owner:XELLSMART BIOMEDICAL (SUZHOU) CO LTD
Method for improving reverse electron transfer rate and energy metabolism level of shewanella single cell by preparing artificial conductive path
Shewanella bacteria are mode electrochemically active bacteria and have bidirectional electron transfer capability, but the reverse electron transfer rate is slower. In order to solve the problem, the invention discloses a method for synchronously constructing an artificial conductive path in shewanella bacteria attachment so as to improve the electron transfer rate of a bacteria-electrode interface and the energy metabolism activity of bacteria. By utilizing the method, after dopamine is subjected to in-situ electropolymerization in the adsorption process of shewanella tamariscina PV-4, polydopamine is formed in a bacterium-electrode interface area, and the current transferred by reverse electrons is improved by 3.46 times. Due to the fact that polydopamine can serve as an artificial conductive path, the reverse electron transfer capacity of shewanella single cells is improved, and the intracellular energy metabolism level is improved through faster electron transfer.
Owner:BEIJING INST OF TECH
Methods and compositions for selective generation of dopaminergic precursors
The present invention provides methods of transdifferentiating a somatic cell, e.g., a fibroblast, to an induced dopaminergic precursor cell (iDP) in vitro. The methods include ectopically expressing genes of (1) one or both of Brn2 and Brn4, or a variant thereof, (2) Sox2, or a variant thereof, and (3) one or both of Foxa2 and Lmx1a, or a variant thereof, in the somatic cell, and methods for treating a neurodegenerative disease, such as Parkinson's disease, with the iDP.
Owner:TONGJI UNIV +1
Therapeutic agent for non-motor symptoms associated with parkinson's disease
The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and / or an effect of preventing the recurrence of the same.
Owner:NEUROINNOVATECH APS
Method of treatment of CNS disorders
The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.
Owner:SUPERNUS PHARMACEUTICALS INC
Method for producing nerve cells
PCT designated stageWO2026141672A1Induced pluripotent stem cellLPA Receptors
The present application provides a method for producing, from pluripotent stem cells, neural progenitor cells of the midbrain floor plate region or dopaminergic neural progenitor cells, the method comprising (1) inducing differentiation of pluripotent stem cells into neural progenitor cells of the midbrain floor plate region, and optionally (2) inducing differentiation of the neural progenitor cells of the midbrain floor plate region, which are obtained by the differentiation induced in (1), into dopaminergic neural progenitor cells, wherein all or part of the differentiation induced in (1) includes culturing the cells in a medium containing an agonist for LPA receptor.
Owner:RACTHERA CO LTD +1
Dopaminergic imaging to predict treatment response in mental illness
A neuroimaging-based approach to predict treatment response in mental disorders by acquiring and analysing brain PET dopamine measures from patients. The method uses a short, simplified protocol for [18F]FDOPA brain PET imaging adapted for clinical practice. Individual [18F]FDOPA brain PET data are then quantified with a fully-automated analysis pipeline to extract information on the dopamine function of the subject. This information coupled with clinical information is run through a prediction algorithm to identify those patients whose illness will not respond to conventional antipsychotics.
Owner:KINGS COLLEGE LONDON
A manganese-based high-performance composite cathode material coated with polydopamine and grown in situ on a MXene material and a preparation method thereof
The application discloses a kind of polydopamine-coated manganese-based high-performance composite positive electrode materials and its preparation method, which is in-situ grown on MXene material, comprising the following steps: (1) preparation of Ni-gamma-MnO2 / MXene;(2) preparation of Ni-gamma-MnO2 / MXene@PDA.This technical solution promotes in-situ growth of nickel and manganese dioxide on MXene substrate by means of hydrothermal synthesis method, to construct a composite material with a specific structure, then, active material containing the above composite structure is uniformly dispersed in tris buffer solution environment, on this basis, oxygen is used as initiator to trigger the polymerization reaction, so that polydopamine can tightly wrap the surface of active material in a highly uniform manner, the preparation process is simple, raw materials are cheap, and the coating of polydopamine can reduce the effective contact degree between aqueous electrolyte and MnO2, reduce the dissolution of MnOOH, and make the structure more stable.
Owner:ZHEJIANG KAN BATTERY CO LTD
Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators
The invention provides certain (phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one related compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, to treat certain symptoms of dopaminergic CNS disorders including Parkinson's disease, Schizophrenia, ADHD or Alzheimer's disease.
Owner:ELI LILLY & CO
Kit for inducing differentiation of stem cells into dopaminergic neural precursor cells and / or dopamine neurons, and use thereof
Provided are a kit for inducing differentiation of stem cells into dopaminergic neural precursor cells and / or dopamine neurons, and a use thereof. The kit uses chemically defined culture media, chemical small molecules and cytokines, and does not involve substances such as animal-derived components which easily cause unstable factors such as batch-to-batch variation. Moreover, the differentiation period is shortened, and the kit can be used in clinical practice.
Owner:XELLSMART BIOMEDICAL (SUZHOU) CO LTD
Nerve cell with conditional immune escape function and suicide function, and establishment method and application thereof
The invention provides a nerve cell with a conditional immune escape function and a suicide function as well as an establishment method and application of the nerve cell. The invention discloses a space-time specific regulation element which can form a space-time specific promoter to regulate the expression of a target gene in a dopaminergic nerve precursor stage (mDAP). In addition, the invention also discloses a modified induced pluripotent stem cell and a nerve cell which is obtained by differentiation and has a conditional immune escape function and a suicide function. The cell can automatically trigger immune escape in the early stage of the dopamine energy precursor, and synchronously has a drug controllable self-destruction function.
Owner:SHANGHAI YUANVORE MEDICINE TECHNOLOGY CO LTD
Use of casein phosphopeptides to facilitate modulation of dopaminergic neurons
The invention belongs to the technical field of food, and relates to novel application of casein phosphopeptides, in particular to application of the casein phosphopeptides in preparation of food beneficial to regulation of dopaminergic neurons of organisms, and regulation of the dopaminergic neurons of the organisms comprises enhancement of the strength of the dopaminergic neurons and / or enhancement of the strength of the dopaminergic neurons. Neurotransmitters and metabolites beneficial to operation of a dopamine energy system are regulated and controlled.
Owner:HEILONGJIANG FEIHE DAIRY CO LTD
Methods and compositions for dosing a cell therapy for parkinson's disease
PCT designated stageWO2026064194A1Nervous disorderUnknown materialsInduced pluripotent stem cellMidbrain
Provided are methods for administering allogeneic induced pluripotent stem cells (iPSC)-derived midbrain dopaminergic progenitors to a subject for treatment of Parkinson's disease (PD). The midbrain dopaminergic progenitor cells are administered to 5 trajectories, each with 8 depositional sites, per putamen. Patients are operated on using a trans-frontal approach with an entry point near the coronal suture. Also provided are compositions and articles of manufacture for use in the methods.
Owner:KENAI THERAPEUTICS INC +1
Temperature-controlled cell incubator for culturing dopaminergic neurons of Parkinson mouse
PendingCN120905023ABioreactor/fermenter combinationsBiological substance pretreatmentsDopaminergicControl cell
The invention discloses a temperature-controlled cell incubator for culturing dopaminergic neurons of Parkinson mice, and relates to the technical field of cell incubators. The device comprises a support, an incubator body is fixedly connected to the top of the support, and an electric temperature controller is fixedly connected to the top of the incubator body. By means of the linkage design of the rotating assembly and the inflation and deflation assembly, dynamic regulation and control of the culture environment are achieved, the rotating rod drives the culture frame to rotate at a low speed, cultured neuron spheres make uniform contact with nutrition and gas, and central necrosis caused by static culture is avoided; cOmixed gas is uniformly sprayed into the culture box, the problem that gas uniformity is damaged by traditional rotary culture is solved, a pure rotary mode or a rotary inflation and deflation mode can be switched through a double-shaft motor and a gear meshing mechanism, the requirements of different experiment stages are met, and the survival rate and function expression of dopaminergic neurons are remarkably improved.
Owner:XUZHOU VOCATIONAL COLLEGE OF BIOENG
Dose regimens for use of LY3154207 in the treatment of dopaminergic CNS disorders
The present invention relates to dosing regimens and methods of using LY3154207, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2 (1H)-yllethanone, and / or pharmaceutical compositions thereof, for treatment of dopaminergic central nervous system disorders. Dopaminergic CNS disorders of the present dosing regimen methods include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia (LBD), Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders.
Owner:ELI LILLY & CO
Stem cell treatment safety evaluation method based on brain organs
The invention provides a brain organ-based stem cell treatment safety evaluation method, which comprises the following steps: S1, constructing a brain organ; s2, preparing cells to be detected, and marking fluorescent protein; s3, injecting the to-be-detected cells with the fluorescent protein markers into the brain organs; and S4, analyzing the to-be-detected cells injected into the brain organs. The invention finds that the dopaminergic cells can maintain normal growth and differentiation in brain organs; the stem cells can maintain high proliferation and dryness in brain organs; residual stem cells can be sensitively detected from brain organs, and the residual stem cells show higher proliferation and dryness in brain tumor organs; meanwhile, compared with mouse brain and whole brain organs, early-stage dopamine precursor cells also show higher proliferation ability in brain tumor organs. In conclusion, the brain organ can be used as a novel tool for safety quality inspection of cell therapy, and potential tumorigenic cells can be more sensitively detected from the brain tumor organ.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV +1
Dopaminergic neural precursor cell cryo- and cryopreservation methods
ActiveCN117502429BSomaDopaminergic
The application provides a dopamine nerve precursor cell freezing solution which is free of serum and animal-derived components, and contains a clinical-grade freezing base solution dextran sodium chloride injection, a non-osmotic cryoprotectant injection-grade human serum albumin (HSA) and an osmotic cryoprotectant injection-grade DMSO, wherein the mass concentration of the non-osmotic cryoprotectant is less than 10% and the mass concentration of the osmotic cryoprotectant is less than 15%, and the dopamine nerve precursor cell freezing solution further contains an additive capable of improving the recovery rate of dopamine nerve precursor cells. The dopamine nerve precursor cell freezing solution provided by the application has simple and clear components, can greatly reduce the damage to cells during the freezing process, significantly improve the recovery rate of cells after resuscitation, maintain the purity and the potential for continuous differentiation of the cells, and is suitable for the storage of clinical-grade dopamine nerve precursor cells at different differentiation stages.
Owner:ANHUI ZHONGSHENG TRACEABLE BIOTECHNOLOGY CO LTD
Therapeutic agent for non-motor symptoms associated with Parkinson's disease
The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and / or an effect of preventing the recurrence of the same.
Owner:NEUROINNOVATECH APS
An electrochemical detection method for dopamine
This invention discloses an electrochemical detection method for dopamine, belonging to the field of analytical technology. The method involves loading SnS2 quantum dots onto a Zn-MOF and modifying it onto an electrode. Subsequently, gold nanoparticles and single chains containing thiol-containing dopamine aptamers are sequentially immobilized onto the electrode, forming an Apt / AuNPs / SnS2QDs@Zn-MOF / GCE composite electrode ("on" state). This significantly enhances the electrochemical signal. Based on the specific recognition between dopamine and the aptamer chain, the large cavity of the Zn-MOF encapsulates the SnS2 quantum dots with excellent electrochemical properties, achieving electrochemical signal amplification. When the target analyte, dopamine, is present, it quenches the ECL signal, resulting in a significant decrease in the electrochemical signal ("off" state). This establishes a linear relationship between the change in electrochemical signal and the dopamine concentration, achieving highly sensitive and selective detection of dopamine.
Owner:JIANGXI NORMAL UNIV
Anti-dat antibodies and compositions thereof
An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of α-syn in the striatum and delaying the course of Parkinson's disease.
Owner:CHINA MEDICAL UNIVERSITY(TW)